"Myocarditis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.
| Descriptor ID |
D009205
|
| MeSH Number(s) |
C14.280.238.625
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Myocarditis".
Below are MeSH descriptors whose meaning is more specific than "Myocarditis".
This graph shows the total number of publications written about "Myocarditis" by people in this website by year, and whether "Myocarditis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 0 | 1 |
| 2003 | 3 | 1 | 4 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 2 | 3 |
| 2008 | 0 | 2 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 3 | 0 | 3 |
| 2011 | 3 | 0 | 3 |
| 2012 | 2 | 0 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 4 | 1 | 5 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 3 | 0 | 3 |
| 2020 | 7 | 1 | 8 |
| 2021 | 13 | 0 | 13 |
| 2022 | 7 | 0 | 7 |
| 2023 | 4 | 0 | 4 |
| 2024 | 4 | 1 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Myocarditis" by people in Profiles.
-
Design and rationale of MYOFLAME-19 randomised controlled trial: MYOcardial protection to reduce post-COVID inFLAMmatory heart disease using cardiovascular magnetic resonance Endpoints. J Cardiovasc Magn Reson. 2025; 27(1):101121.
-
Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis. Cancer Immunol Res. 2024 Aug 01; 12(8):964-987.
-
Use of positron emission tomography for the diagnosis of immune-checkpoint inhibitor| myocarditis. J Nucl Cardiol. 2024 Sep; 39:101909.
-
Cardiovascular toxicity of immune therapies for cancer. BMJ. 2024 05 15; 385:e075859.
-
Myocarditis in children 2024, new themes and continued questions. Curr Opin Cardiol. 2024 Jul 01; 39(4):315-322.
-
Celiac Disease and the Risk of Cardiovascular Diseases. Int J Mol Sci. 2023 Jun 09; 24(12).
-
Contemporary Care and Outcomes of Critically-ill Children With Clinically Diagnosed Myocarditis. J Card Fail. 2024 Feb; 30(2):350-358.
-
Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis. Ann Rheum Dis. 2023 06; 82(6):829-836.
-
Shedding Light on Mechanisms of Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2023 03 14; 147(11):877-880.
-
Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. 2022 09 10; 75(4):673-681.